Verona Pharma is a biopharmaceutical company focused on developing and commercializing treatments for respiratory diseases. Their product candidate, ensifentrine, is a dual inhibitor that acts as both a bronchodilator and anti-inflammatory agent. The company is currently in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.